Theravance Biopharma Management
Management criteria checks 3/4
Theravance Biopharma's CEO is Rick Winningham, appointed in Jun 2014, has a tenure of 10.08 years. total yearly compensation is $4.32M, comprised of 24.3% salary and 75.7% bonuses, including company stock and options. directly owns 3.97% of the company’s shares, worth $18.11M. The average tenure of the management team and the board of directors is 2.1 years and 6.4 years respectively.
Key information
Rick Winningham
Chief executive officer
US$4.3m
Total compensation
| CEO salary percentage | 24.3% |
| CEO tenure | 10.1yrs |
| CEO ownership | 4.0% |
| Management average tenure | 2.1yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now
May 02
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Theravance Biopharma EPS misses by $0.16, misses on revenue
May 04Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why
Apr 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$4m | US$1m | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$61m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$75m |
| Dec 31 2022 | US$6m | US$1m | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$136m |
| Jun 30 2022 | n/a | n/a | -US$196m |
| Mar 31 2022 | n/a | n/a | -US$226m |
| Dec 31 2021 | US$4m | US$1m | -US$265m |
| Sep 30 2021 | n/a | n/a | -US$266m |
| Jun 30 2021 | n/a | n/a | -US$264m |
| Mar 31 2021 | n/a | n/a | -US$275m |
| Dec 31 2020 | US$7m | US$1m | -US$295m |
| Sep 30 2020 | n/a | n/a | -US$285m |
| Jun 30 2020 | n/a | n/a | -US$270m |
| Mar 31 2020 | n/a | n/a | -US$247m |
| Dec 31 2019 | US$6m | US$984k | -US$236m |
| Sep 30 2019 | n/a | n/a | -US$221m |
| Jun 30 2019 | n/a | n/a | -US$222m |
| Mar 31 2019 | n/a | n/a | -US$223m |
| Dec 31 2018 | US$3m | US$957k | -US$216m |
| Sep 30 2018 | n/a | n/a | -US$252m |
| Jun 30 2018 | n/a | n/a | -US$260m |
| Mar 31 2018 | n/a | n/a | -US$285m |
| Dec 31 2017 | US$2m | US$933k | -US$285m |
Compensation vs Market: Rick's total compensation ($USD4.32M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
CEO
Rick Winningham (64 yo)
10.1yrs
Tenure
US$4,318,531
Compensation
Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022 . He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Compa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 10.1yrs | US$4.32m | 3.97% $ 18.1m | |
| Senior VP & CFO | 1.5yrs | US$1.39m | 0.68% $ 3.1m | |
| Senior VP of IT&I and Chief Information Officer | no data | no data | no data | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior VP | 2.1yrs | no data | 0.72% $ 3.3m | |
| Chief Business Officer and Senior VP of Commercial & Medical Affairs | 2.6yrs | US$942.81k | 0.69% $ 3.1m | |
| Senior VP & Chief Strategy Officer | 1.8yrs | no data | no data | |
| SVP of Dev. | no data | no data | 0.34% $ 1.6m |
2.1yrs
Average Tenure
54.5yo
Average Age
Experienced Management: TBPH's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 11yrs | US$4.32m | 3.97% $ 18.1m | |
| Independent Director | 10.1yrs | US$205.14k | 0.14% $ 656.1k | |
| Independent Director | 4yrs | US$207.68k | 0.098% $ 444.3k | |
| Lead Independent Director | 10.1yrs | US$211.73k | 0.17% $ 754.8k | |
| Independent Director | 1.3yrs | US$43.10k | no data | |
| Independent Director | 8.8yrs | US$195.80k | 0.13% $ 595.5k | |
| Independent Director | 1.4yrs | US$346.47k | 0.065% $ 295.1k | |
| Independent Director | 6.4yrs | US$197.68k | 0.13% $ 602.8k | |
| Independent Director | less than a year | US$168.36k | 0.046% $ 209.0k |
6.4yrs
Average Tenure
64.5yo
Average Age
Experienced Board: TBPH's board of directors are considered experienced (6.4 years average tenure).